The GRK6 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the GRK6 gene in the HEK293T human embryonic kidney cell line. This heterogeneous pool of edited cells provides a robust loss-of-function model for studying G protein-coupled receptor kinase 6 (GRK6) functions without the selective pressure or clonal artifacts inherent to single-cell-derived knockout lines. By employing CRISPR/Cas9-mediated gene disruption, the product ensures broad representation of GRK6 null mutations across the cell population, facilitating reproducible interrogation of GPCR signaling networks.
HEK293T cells are an extensively characterized adherent epithelial cell line derived from human embryonic kidney, stably expressing the SV40 large T antigen. This modification enables high-level episomal replication of plasmids containing the SV40 origin of replication, making HEK293T the preferred host for transient protein expression and lentivirus production. The cells retain a near-diploid karyotype and express a repertoire of endogenous adhesion molecules and signaling proteins, providing a physiologically relevant background for studying GPCR biology. Their rapid growth, ease of transfection, and compatibility with high-throughput platforms have established HEK293T as a workhorse in academic and pharmaceutical research.
GRK6 is a member of the GRK4 subfamily of serine/threonine kinases that selectively phosphorylate agonist-activated GPCRs, initiating receptor desensitization and internalization. Mechanistically, GRK6 is recruited to the plasma membrane by heterotrimeric G protein ?¦? subunits and phosphatidylinositol 4,5-bisphosphate (PIP2), where it phosphorylates serine and threonine residues within the C-terminal tail or intracellular loops of target receptors. This phosphorylation promotes high-affinity binding of ??-arrestin-1 (ARRB1) or ??-arrestin-2 (ARRB2), which sterically uncouple the receptor from G proteins and serve as adaptors for clathrin-mediated endocytosis via interactions with the clathrin adaptor AP-2 complex. Beyond desensitization, ??-arrestins scaffold mitogen-activated protein kinase cascades, including ERK1/2, thereby switching receptor signaling toward G protein-independent pathways. GRK6 activity is modulated by upstream regulators such as protein kinase C (PKC) and receptor-activated G?¦?, and it interacts with calmodulin and actin, integrating calcium and cytoskeletal signals. Key downstream effectors include phosphorylated GPCRs, ??-arrestin isoforms, clathrin adaptor AP-2, and ERK1/2, positioning GRK6 at a central node controlling receptor trafficking and biased signaling.
In the HEK293T background, GRK6 knockout offers a unique platform to dissect GPCR regulatory mechanisms. Endogenous expression of multiple GPCR subfamilies, including chemokine receptors (e.g., CXCR4) and dopamine D2-like receptors, allows investigation of GRK6-dependent desensitization in a native cellular context. Transient or stable overexpression of GPCRs in these knockout cells facilitates structure?Cfunction studies of receptor phosphorylation barcodes and arrestin coupling without interference from wild-type GRK6. Moreover, the polyclonal nature of the population mitigates off-target effects and provides a more representative sampling of gene disruption events, enhancing the reliability of functional complementation assays where GRK6 mutants or isoforms are reintroduced. This model is particularly valuable for characterizing biased agonists that preferentially activate G protein or arrestin pathways, as the absence of GRK6 alters the equilibrium between these signaling modalities.
Typical applications include quantitative analysis of receptor internalization via immunofluorescence microscopy or ??-arrestin recruitment BRET assays, measurement of cAMP accumulation to assess G protein-mediated signaling, phospho-ERK1/2 detection to monitor arrestin-dependent cascades, and chemotaxis assays for chemokine receptor function. Researchers can employ western blotting to confirm loss of GRK6 protein and correlate with changes in receptor phosphorylation status. The cells are also suitable for high-content screening of allosteric modulators and GRK inhibitors in neuropsychiatric and inflammatory disease contexts, where aberrant GRK6 activity has been implicated. For further technical specifications or to discuss custom gene-editing services, please contact Ascent Research.
